Study Details

Open

Relapsed or Refractory Multiple Myeloma Treatment Study

In this study, we want to see if a new medicine is safe and works well for adults with multiple myeloma cancer. These adults have already tried at least two other treatments, including specific types of medicines. This study can help us discover a new, safer treatment for this type of cancer.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)
Visits can be combined with regular clinical appointments

Location

North Carolina (Statewide)

What will be asked of you

During screening, you will fill out questionnaires and fill out forms. The study also involves a physical exam, blood and urine tests, pregnancy test, bone marrow biopsy, CT scan, SARS-CoV-2 testing, and Hepatitis B and C testing.

Incentives

You will be reimbursed for travel expenses that you incur for each study visit. You or your insurance provider will not have to pay for the ABBV-383, carfilzomib, elotuzumab, pomalidomide, selinexor, bortezomib, or dexamethasone while you take part in this study.

Total length of participation:
You will receive study treatment until you meet criteria for discontinuation. After treatment ends, you will move to the follow-up portion of the trial.

Looking for Specific Volunteers

Able to participate:

You must be diagnosed with relapsed and/or refractory multiple myeloma during or after your last treatment.
You need to have measurable disease within 28 days before you can join the study.
You need to have tried at least two different kinds of treatment for your condition, including a PI, an IMiD, and an anti-CD38 mAb.
You should either have enough bone marrow stored from before within 12 weeks before starting treatment or agree to have new bone marrow collected.
You must be eligible to receive and accept the investigator's choice of standard available therapies (SAT).

Not eligible if:

You have a history of significant cardiovascular or pericardial disease.
You have a history with any type of cancer the past 3 years with some exceptions.
You have received BCMA-targeted therapy.
You have known central nervous system involvement of multiple myeloma.
You have a known allergy, hypersensitivity, or intolerance to the study drug.

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Trials Office
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Secondary Visit Location

UNC Hospitals Hillsborough Campus
460 Waterstone Dr, Hillsborough, NC 27278, USA

Additional Study Information

Principal Investigator

Eben Lichtman
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Blood Conditions
Cancer (Multiple Myeloma)

IRB Number

24-0396

ClinicalTrials.gov

NCT06158841